VCR PR Machine beginning to churn......
We were very impressed by this device. We thought that it had a low complication rate, it's very small.
Dr Deborah Meyers, Prince Charles Hospital 12/09/07
Ventracor is moving to an important inflexion point for the commercialisation of its technology. A profitable market currently exists for LVADs and there is a positive swing in events that is likely to see a wider adoption of LVADs into the far larger market of destination therapy, which is estimated to be in excess of 25,000 implants a year.
BioShares investment newsletter 22/06/07
Hoping they can get US investors on board during the conference next week, needed to get SP moving!
VCR
ventracor limited
